.. Antibe Therapeutics completes pre-clinical program for its lead product ATB-346 Antibe Therapeutics Inc. is pleased to announce that it has completed its prepared pre-clinical program because of its lead product ATB-346 to aid initial clinical studies in humans. ATB-346 targets the global need for a GI-safe anti-inflammatory painkiller, a growing market that currently generates annual sales of over $12 billion. Said Chief Scientific Officer Dr. John Wallace, We are delighted that the planned pre-clinical research have been finished, and that these studies confirm and expand upon the extensive academic function already conducted on ATB-346..
Cancer drug helps prevent hypertensive heart disease A promising cancer treatment drug may restore function of a center en route to failing from high blood circulation pressure, experts at UT Southwestern Medical Center have found. The drug, a type of histone deacetylase inhibitor being evaluated in various ongoing clinical trials, has been proven to reverse the harmful ramifications of autophagy in center muscles cells of mice. Autophagy is a natural process where cells eat their own proteins to provide needed resources in instances of stress. The new study shows up in Proceedings of the National Academy of Sciences. This opens just how for a fresh therapeutic strategy in hypertensive heart disease, one we can check for potential to promote regression of cardiovascular disease, said Dr.